FDA Seeks New Warnings on Antidepressants and "Suicidality"

By Admin on May 02, 2007 | Last updated on March 21, 2019

The U.S. Food and Drug Administration (FDA) has proposed that makers of all antidepressant medications update the existing "black box" warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior (known as "suicidality") in young adults ages 18 to 24 during the first one to two months of treatment. The FDA announcement applies to all antidepressants, including Celexa, Effexor, Fluvoxamine, Lexapro, Paxil, Prozac, Seroquel, Symbyax, and Zoloft,. The FDA advises people currently prescribed antidepressant medications to continue taking them, but to notify their health care providers if they have concerns.

  • Read the FDA Press Release
  • FDA's New Drug Safety Initiative
Copied to clipboard